Xenon Pharmaceuticals ROA 2012-2022 | XENE
Current and historical return on assets (ROA) values for Xenon Pharmaceuticals (XENE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Xenon Pharmaceuticals ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-03-31 |
$-0.08B |
$0.56B |
-19.41% |
| 2021-12-31 |
$-0.08B |
$0.57B |
-21.97% |
| 2021-09-30 |
$-0.06B |
$0.26B |
-25.12% |
| 2021-06-30 |
$-0.06B |
$0.28B |
-24.32% |
| 2021-03-31 |
$-0.04B |
$0.29B |
-16.18% |
| 2020-12-31 |
$-0.03B |
$0.19B |
-13.40% |
| 2020-09-30 |
$-0.03B |
$0.20B |
-13.58% |
| 2020-06-30 |
$-0.03B |
$0.21B |
-15.54% |
| 2020-03-31 |
$-0.04B |
$0.24B |
-25.08% |
| 2019-12-31 |
$-0.04B |
$0.15B |
-35.04% |
| 2019-09-30 |
$-0.04B |
$0.10B |
-35.29% |
| 2019-06-30 |
$-0.04B |
$0.11B |
-36.36% |
| 2019-03-31 |
$-0.04B |
$0.12B |
-36.11% |
| 2018-12-31 |
$-0.03B |
$0.12B |
-36.06% |
| 2018-09-30 |
$-0.03B |
$0.13B |
-44.44% |
| 2018-06-30 |
$-0.03B |
$0.07B |
-53.33% |
| 2018-03-31 |
$-0.03B |
$0.04B |
-58.70% |
| 2017-12-31 |
$-0.03B |
$0.05B |
-59.90% |
| 2017-09-30 |
$-0.03B |
$0.05B |
-50.88% |
| 2017-06-30 |
$-0.03B |
$0.05B |
-45.49% |
| 2017-03-31 |
$-0.03B |
$0.06B |
-43.58% |
| 2016-12-31 |
$-0.02B |
$0.07B |
-35.80% |
| 2016-09-30 |
$-0.02B |
$0.07B |
-33.07% |
| 2016-06-30 |
$-0.02B |
$0.06B |
-27.09% |
| 2016-03-31 |
$-0.01B |
$0.06B |
-14.71% |
| 2015-12-31 |
$-0.02B |
$0.06B |
-22.07% |
| 2015-09-30 |
$-0.00B |
$0.07B |
-3.83% |
| 2015-06-30 |
$0.01B |
$0.08B |
6.73% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.599B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
